Literature DB >> 27269372

Contextual signaling in cancer.

Laura J Smithson1, Corina Anastasaki1, Ran Chen1, Joseph A Toonen1, Sidney B Williams1, David H Gutmann2.   

Abstract

The formation and maintenance of an organism are highly dependent on the orderly control of cell growth, differentiation, death, and migration. These processes are tightly regulated by signaling cascades in which a limited number of molecules dictate these cellular events. While these signaling pathways are highly conserved across species and cell types, the functional outcomes that result from their engagement are specified by the context in which they are activated. Using the Neurofibromatosis type 1 (NF1) cancer predisposition syndrome as an illustrative platform, we discuss how NF1/RAS signaling can create functional diversity at multiple levels (molecular, cellular, tissue, and genetic/genomic). As such, the ability of related molecules (e.g., K-RAS, H-RAS) to activate distinct effectors, as well as cell type- and tissue-specific differences in molecular composition and effector engagement, generate numerous unique functional effects. These variations, coupled with a multitude of extracellular cues and genomic/genetic changes that each modify the innate signaling properties of the cell, enable precise control of cellular physiology in both health and disease. Understanding these contextual influences is important when trying to dissect the underlying pathogenic mechanisms of cancer relevant to molecularly-targeted therapeutics.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Astrocyte; Glioma; NF1; Nervous system; Neuron; RAS; mTOR

Mesh:

Substances:

Year:  2016        PMID: 27269372      PMCID: PMC5028257          DOI: 10.1016/j.semcdb.2016.06.002

Source DB:  PubMed          Journal:  Semin Cell Dev Biol        ISSN: 1084-9521            Impact factor:   7.727


  67 in total

Review 1.  Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention.

Authors:  F Chang; L S Steelman; J T Lee; J G Shelton; P M Navolanic; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-07       Impact factor: 11.528

2.  Neurofibromatosis-1 regulates neuroglial progenitor proliferation and glial differentiation in a brain region-specific manner.

Authors:  Da Yong Lee; Tu-Hsueh Yeh; Ryan J Emnett; Crystal R White; David H Gutmann
Journal:  Genes Dev       Date:  2010-09-28       Impact factor: 11.361

3.  NF1 germline mutation differentially dictates optic glioma formation and growth in neurofibromatosis-1.

Authors:  Joseph A Toonen; Corina Anastasaki; Laura J Smithson; Scott M Gianino; Kairong Li; Robert A Kesterson; David H Gutmann
Journal:  Hum Mol Genet       Date:  2016-02-16       Impact factor: 6.150

4.  Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways.

Authors:  J L Arbiser; M A Moses; C A Fernandez; N Ghiso; Y Cao; N Klauber; D Frank; M Brownlee; E Flynn; S Parangi; H R Byers; J Folkman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

5.  K-ras is essential for the development of the mouse embryo.

Authors:  K Koera; K Nakamura; K Nakao; J Miyoshi; K Toyoshima; T Hatta; H Otani; A Aiba; M Katsuki
Journal:  Oncogene       Date:  1997-09-04       Impact factor: 9.867

6.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406

7.  Akt regulates growth by directly phosphorylating Tsc2.

Authors:  Christopher J Potter; Laura G Pedraza; Tian Xu
Journal:  Nat Cell Biol       Date:  2002-09       Impact factor: 28.824

Review 8.  Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression.

Authors:  Jiyong Liang; Joyce M Slingerland
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

9.  Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/- mast cells.

Authors:  Andrew S McDaniel; Jayme D Allen; Su-Jung Park; Zahara M Jaffer; Elizabeth G Michels; Sarah J Burgin; Shi Chen; Waylan K Bessler; Clemens Hofmann; David A Ingram; Jonathan Chernoff; D Wade Clapp
Journal:  Blood       Date:  2008-09-02       Impact factor: 22.113

10.  p.Arg1809Cys substitution in neurofibromin is associated with a distinctive NF1 phenotype without neurofibromas.

Authors:  Valentina Pinna; Valentina Lanari; Paola Daniele; Federica Consoli; Emanuele Agolini; Katia Margiotti; Irene Bottillo; Isabella Torrente; Alessandro Bruselles; Caterina Fusilli; Anna Ficcadenti; Sara Bargiacchi; Eva Trevisson; Monica Forzan; Sandra Giustini; Chiara Leoni; Giuseppe Zampino; Maria Cristina Digilio; Bruno Dallapiccola; Maurizio Clementi; Marco Tartaglia; Alessandro De Luca
Journal:  Eur J Hum Genet       Date:  2014-11-05       Impact factor: 4.246

View more
  4 in total

Review 1.  Intracellular and intercellular signaling networks in cancer initiation, development and precision anti-cancer therapy: RAS acts as contextual signaling hub.

Authors:  Peter Csermely; Tamás Korcsmáros; Ruth Nussinov
Journal:  Semin Cell Dev Biol       Date:  2016-07-06       Impact factor: 7.727

2.  The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas.

Authors:  A Pemov; H Li; R Patidar; N F Hansen; S Sindiri; S W Hartley; J S Wei; A Elkahloun; S C Chandrasekharappa; J F Boland; S Bass; J C Mullikin; J Khan; B C Widemann; M R Wallace; D R Stewart
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

Review 3.  Oncogenic Ras Isoforms Signaling Specificity at the Membrane.

Authors:  Ruth Nussinov; Chung-Jung Tsai; Hyunbum Jang
Journal:  Cancer Res       Date:  2017-12-22       Impact factor: 12.701

4.  Caddyshack therapeutics: overcoming glioblastoma adaptation.

Authors:  David H Gutmann
Journal:  Neuro Oncol       Date:  2017-10-19       Impact factor: 12.300

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.